ID   NTERA-2-R
AC   CVCL_C0QJ
DR   PRIDE; PXD030251
DR   Wikidata; Q112930238
RX   PubMed=35084545;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Omics: Proteomics; Quantitative.
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3752; Embryonal carcinoma
DI   ORDO; Orphanet_180226; Embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0034 ! NTERA-2
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 6
//
RX   PubMed=35084545; DOI=10.1007/s00345-022-03936-1; PMCID=PMC8921118;
RA   Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C.,
RA   Strobel P., Kueffer S., Nettersheim D., Bremmer F.;
RT   "Proteomic profiling of cisplatin-resistant and cisplatin-sensitive
RT   germ cell tumour cell lines using quantitative mass spectrometry.";
RL   World J. Urol. 40:373-383(2022).
//